NRAS G12V
Clinical trials for NRAS G12V explained in plain language.
Never miss a new study
Get alerted when new NRAS G12V trials appear
Sign up with your email to follow new studies for NRAS G12V, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New targeted drug hopes to shrink Hard-to-Treat melanoma
Disease control Recruiting nowThis early-stage study tests a new drug called RLY-8161 in people with advanced melanoma or other solid tumors that have a specific NRAS gene mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 35 participants will take the drug by mouth,…
Matched conditions: NRAS G12V
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:55 UTC
-
New immunotherapy option for pancreatic cancer patients with no other choices
Disease control AVAILABLEThis program provides early access to an experimental immunotherapy called ELI-002 7P for people with a specific type of pancreatic cancer (KRAS/NRAS-mutated) who have had their tumor removed but are at high risk of the cancer coming back. It is for patients who have no other tre…
Matched conditions: NRAS G12V
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC